학술논문
There are several treatment options for castration-resistant prostate cancer (CRPC). The order in which to use these agents is not well defined, so selection is dependent on clinical symptoms and the adverse effect profiles of the agents. Molecular testing is becoming more common with CRPC and will likely be used in the future for therapy selection.
Document Type
Article
Author
Source
Journal of Managed Care Medicine; 2018, Vol. 21 Issue 2, p9-13, 5p, 2 Diagrams, 1 Chart, 1 Graph
Subject
Language
ISSN
10941525